Roche on efficacy and safety of risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020

Roche has hosted a live audio webcast and conference call on Thursday, 6 February 2020.


Agenda:
Welcome	Karl Mahler, Head of Investor Relations
Phase II/III SUNFISH part 2 data - efficacy and safety of risdiplam in patients with type 2 or type 3 SMA	Paulo Fontoura, Global Head Neuroscience and Rare Diseases Clinical Development
Q&A

Webinar Replay

Downloads

Presentation

PDF

Related links

GovernanceAbout Roche

Our corporate governance principles focus on sustainable value creation and promote a culture that recognises standards of good corporate governance and a commitment to transparent communication.

Roche’s Annual Report 2019Investors

How medicines are making an impact in the lives of patients

Product Development PipelineSolutions

Discover our pipeline of Pharmaceutical and Diagnostics developments

Frequently asked questionsInvestors

We answer the Roche investors-related most frequently asked questions